# US 2024/0197772 A1 · COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LacNAc-Lac

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197772 A1
- Document ID: US20240197772A1
- Status: Published application
- Kind: A1
- Application number: 17/909,854
- Filed: 2021-03-24
- Published: 2024-06-20
- Earliest claimed: 2020-03-25
- Assignees: FrieslandCampina Nederland B.V.
- Applicants: FrieslandCampina Nederland B.V.
- Inventors: Vassilios TRIANTIS
- Web page: https://patentgrep.com/patent/US20240197772A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 31/738: Cross-linked polysaccharides
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A synthetic composition comprising one or more compounds according to formula (1), or a pharmaceutically acceptable salt, solvate or ester thereof, for use in the modulation of one or more of: i. the cholesterol level; ii. lipolysis; iii. glucose uptake; iv. CD36 receptor activity; wherein the compound of Formula 1 is Yn→D-Gal-β1→3-(Ym→)(Xp→)D-GcNAc-β1→3-D-Gal-β1→4-(Xq→)-D-Glc (Formula (1)), wherein X is α-L-Fucose (α-L-Fuc), Y is N-acetyl-D-neuraminic acid (Neu5Ac-α-2-), n, m, p, q indicate the number of the monosaccharide residues present in the compound of formula (1) and n is 0 or 1; m is 0 or 1; p is 0 or 1; q is 0 or 1; and n+m+p+q≥1.

## Claims

### Claim at position 1

1: A method of modulating one or more of:
i. a cholesterol level;
ii. lipolysis;
iii. glucose uptake; and
iv. CD36 receptor activity;
in a subject, the method comprising administering to the subject an effective amount of compound according to Formula 1, or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the compound of Formula 1 is
Yn→D-Gal-β1→3-(Ym→)(Xp→)D-GlcNAc-β1→3-D-Gal-β1→4-(Xq→)-D-Glc Formula 1
wherein in Formula 1:
X is α-L-Fucose (α-L-Fuc),
Y is N-acetyl-D-neuraminic acid (Neu5Ac-α-2-),
n, m, p, q indicate the number of the monosaccharide residues present in the compound of Formula 1 and n is 0 or 1; m is 0 or 1; p is 0 or 1; q is 0 or 1;
and n+m+p+q≥1.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the method of modulating is selected from one or more of the group consisting of reducing of the cholesterol level, enhancing lipolysis, increasing glucose uptake, and decreasing of CD36 receptor levels.

### Claim at position 3 (depends on 1)

3: The method of claim 1, wherein the method of modulating is a modulating of tissue cholesterol levels.

### Claim at position 4 (depends on 1)

4: The method of claim 1, wherein the composition comprises two or more compounds according to Formula 1.

### Claim at position 5 (depends on 1)

5: The method of claim 1, wherein the compound of Formula 1 is selected from the group consisting of lactodifucoheaxose II (LNDFHII), sialyllacto-N-tetraose a (LSTa) or disialyllacto-N-tetraose (DSLNT), or a combination thereof.

### Claim at position 6 (depends on 1)

6: The method of claim 1, wherein the composition further comprises fat, protein and carbohydrate.

### Claim at position 7 (depends on 1)

7: The method of claim 1, wherein the composition is an infant formula or wherein the composition is an adult formula.

### Claim at position 8 (depends on 1)

8: The method of claim 1, wherein the composition is a food product selected from the group consisting of confectionary products; nutritionally complete food products; desserts; beverages; breakfasts; soups; and sauces.

### Claim at position 9 (depends on 1)

9: The method of claim 1, wherein the composition is further comprising one or more human milk oligosaccharides (HMOs) other than a compound according to Formula 1.

### Claim at position 10 (depends on 1)

10: The method of claim 1, wherein the composition is further comprising one or more probiotics and/or one or more prebiotics.

### Claim at position 11 (depends on 1)

11: The method of claim 1, wherein the composition is further comprising a biologically effective amount of lactoferrin.

### Claim at position 12 (depends on 1)

12: The method of claim 1, wherein the composition does not comprise purified adiponectin or a biologically active fragment thereof.

### Claim at position 13 (depends on 1)

13: The method of claim 1, wherein the composition is further comprising soluble CD14.

### Claim at position 14 (depends on 1)

14: The method of claim 1, wherein the amount of compound according to Formula 1 is between 0.001 wt % and 15 wt % of total dry weight of the composition.

### Claim at position 15 (depends on 1)

15: The method of claim 1, wherein the subject is a human subject.

### Claim at position 16 (depends on 6)

16: The method of claim 6, wherein the fat is a mixture of vegetable fat and milk fat.

### Claim at position 17 (depends on 7)

17: The method of claim 7, wherein the composition is a formula for children having an age selected from the group consisting of 0-6 months, 0-12 months, 6-12 months 12-24 months, 12-36 months, and 24-36 months.

### Claim at position 18 (depends on 9)

18: The method of claim 9, wherein the composition is further comprising LNFP II or LNFP III.

### Claim at position 19 (depends on 11)

19: The method of claim 11, wherein the composition is further comprising more than 0.01 wt % of lactoferrin based on dry weight of the composition.

### Claim at position 20 (depends on 14)

20: The method of claim 14, wherein the amount of compound according to Formula 1 is between 0.01 wt % and 10 wt % of total dry weight of the composition.
